Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
CAR-PRISM phase 2 trial of Ciltacabtagene autoleucel in high-risk smoldering myeloma finds all patients achieved MRD negativity 10-6 by 2 mos & have remained negative; CRS in 100%, non-ICANS neurologic toxicities in 35%.”
Title: Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Authors: Omar Nadeem, David M. Cordas dos Santos, Sarah Nikiforow, Anna Bosch-Vilaseca, Elizabeth O’Donnell, Robert Redd, Kevin C. DeBraganca, Adam S. Sperling, Yuxin Liu, Caleb McEntire, Frances Arters, Colin O’Donnell, Brendan Kineavy, Marjorie Marto, Amy Bergeron, Emilie Swenson, Kristin McHugh, Abigail Caron, Quentin Berry, Hope Wei, Emily Durlacher, Elizabeth Grimm, Francesco Corrado, Nayda Bidikian, Rocio Montes de Oca, Tamar Lengil, Denise De Wiest, Casey Gervais, Kevin Panaro, Eric L. Smith, Kenneth Anderson, Caron Jacobson, Nikhil C. Munshi, Paul Richardson, Deepu Madduri, Jordan M. Schecter, Craig Tendler, Mark A. Wildgust, Lorenzo Trippa, Maria Victoria Mateos, Jerome Ritz, Irene M. Ghobrial
You can read the Full Article in Nature Medicine.
You can find other articles featuring Robert Orlowski on OncoDaily.
